Archives
- 2026-11
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
BI-1347: CDK8 Signaling Workflow Guide
2026-09-18
BI-1347 is a potent, selective small-molecule probe for testing target-dependent signaling and antitumor biology. This workflow translates CDK8/19-focused findings from osteoarthritis research into practical cell-based, inflammatory, transcriptomic, and translational assay designs.
Nilotinib (AMN-107) Assay Workflows
2026-09-18
Build more informative kinase-response experiments with Nilotinib (AMN-107), from BCR-ABL target engagement to separate measurements of growth arrest and cell death. This workflow combines practical dosing guidance, mutation-aware comparisons, and troubleshooting for chronic myeloid leukemia research and KIT-driven models.
CUDC-907: Practical Dual PI3K/HDAC Workflow
2026-09-17
CUDC-907 provides a research tool for examining concurrent PI3K/AKT signaling pathway inhibition and histone deacetylase inhibition in controlled cancer cell assays. This guide covers preparation, exposure, controls, and endpoint QC; the compound is for research use only and should not be used for diagnostic, therapeutic, or clinical applications.
RSL3: A Context-Aware GPX4 Assay Strategy
2026-09-17
RSL3 is a glutathione peroxidase 4 inhibitor that can reveal how metabolic state controls ferroptosis sensitivity. This guide uses bladder cancer MCT4 research to build a more discriminating assay and interpretation framework for cancer biology.
Trametinib: From MEK Inhibition to Neural ERK Biology
2026-09-16
Trametinib (GSK1120212) is more than an oncology pathway probe: it can help dissect how oxidative signals reach ERK1/2 in sensory neurons. This article connects MEK inhibition, BH4-derived H2O2 signaling, and assay design while defining the translational limits of cross-domain interpretation.
SR-202: PPARγ Antagonist Workflow Guide
2026-09-16
SR-202 enables controlled inhibition of PPARγ to separate receptor-dependent adipogenesis, metabolic signaling, and macrophage responses from nonspecific cell effects. This workflow guide connects validated PPARγ biology with practical assay design for insulin resistance research, obesity research, and hypothesis-driven immunometabolic studies.
Pseudo-UTP for Smarter mRNA Synthesis
2026-09-15
Pseudo-UTP enables controlled replacement of UTP during in vitro transcription to support more persistent, efficiently translated RNA. This practical guide connects nucleotide substitution with mRNA vaccine development, assay design, quality control, and troubleshooting.
Regorafenib, RRM2, and Melanoma Progression
2026-09-15
The 2024 iScience study identifies RRM2 as a mechanistic downstream target through which Regorafenib suppresses melanoma cell growth, invasion, and metastasis. Its combination of RNA sequencing, functional perturbation, pathway analysis, and in vivo validation provides a useful framework for studying multikinase inhibitor responses beyond angiogenesis.
BRCAness and Olaparib Sensitivity in Mesothelioma
2026-09-14
Borchert et al. linked homologous recombination repair defects, including BAP1-associated BRCAness, with olaparib sensitivity in malignant pleural mesothelioma models. Their integrated cell-line and clinical-sample strategy supports molecular stratification of mesothelioma while emphasizing that the findings remain preclinical and require prospective validation.
Ruxolitinib, DRP1, and ATC Cell Death
2026-09-14
A 2024 Cell Death and Disease study identifies a mechanistic link between JAK1/2–STAT3 signaling, DRP1-dependent mitochondrial fission, apoptosis, and GSDME-mediated pyroptosis in anaplastic thyroid carcinoma. Its in vitro and in vivo findings position transcriptional control of mitochondrial dynamics as an important component of ruxolitinib activity in this aggressive tumor context.
Nocodazole as a Translational Cell-Cycle Probe
2026-09-13
Nocodazole is more than a mitotic-arrest reagent: its reversible control of β-tubulin and microtubule dynamics can help translational researchers connect cytoskeletal state, mitotic progression, cap-dependent translation, and cancer phenotypes. This article presents a mechanism-led framework for experimental validation, assay design, reagent selection, and preclinical interpretation.
Ganetespib: From Hsp90 Mechanism to Assay Insight
2026-09-12
Ganetespib and STA-9090 offer a powerful framework for studying Hsp90-dependent tumor biology. This article connects its cancer research applications with a landmark norovirus secretion study to show how causal, orthogonal assay design can improve mechanistic interpretation.
Troglitazone: From PPARγ Biology to SPP1 Strategy
2026-09-11
Troglitazone offers a useful PPARγ-centered research entry point for connecting lipid and glucose metabolism with tumor-myeloid biology. This thought-leadership article translates SPP1-focused macrophage screening into a rigorous strategy for testing whether nuclear-receptor perturbation can reprogram SPP1-high tumor-associated macrophages without confusing hypothesis with established evidence.
ARCA Cy5 EGFP mRNA: A Dual-Readout Benchmark
2026-09-11
ARCA Cy5 EGFP mRNA (5-moUTP) separates mRNA uptake from productive protein expression in mammalian cells. This article shows how to use its dual fluorescence design to make delivery-system comparisons more mechanistically informative, drawing on nanoparticle stability research.
IPR-803: From uPAR Binding to Stromal Remodeling
2026-09-10
IPR-803 is a urokinase receptor inhibitor that connects direct uPAR–uPA blockade with invasion, angiogenesis, and pancreatic tumor-stroma research. This guide translates its biochemical, cellular, and nanomedicine evidence into practical assay decisions.
7805 records 6/521 page Previous Next First page 上5页 678910 下5页 Last page